Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Chronic noncancer pain is now considered a global epidemic and a public health problem in the United States, partly owing to its prevalence, underdiagnosis, and undertreatment.
Clinical Assessment of Abuse-Deterrent Formulations
Ofer M. Wellisch, MD, MPH
Read More
In Vitro and Clinical Assessments of Abuse-Deterrent Formulations for Chronic Pain
Sabby Muneer, PhD
Read More
In Vitro and Clinical Assessments of Abuse-Deterrent Formulations in the Management of Chronic Pain
Gary M. Owens, MD
Read More
The Tip of the Iceberg
Atheer A. Kaddis, PharmD
Read More
Results 1 - 4 of 4